FDA must publish OTC drug approval timelines and negotiation records
S. 2513 — OTC Monograph Drug User Fee Transparency Act · Filed by Tim Kaine (D-VA) · Introduced Jul 29, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the FDA to publish detailed annual reports on its processing of over-the-counter (OTC) drug monograph applications—including how many applications were approved, timelines, and safety monitoring activities—and to make public the minutes of negotiation meetings between the FDA and drug manufacturers within 30 days. It also directs the Government Accountability Office to study the OTC drug supply chain and report back within two years on whether the FDA has adequate tools to monitor and prevent disruptions.
Why we flagged it
The bill's core mechanism is mandating public disclosure of FDA reporting and negotiation records related to OTC drug approvals and supply-chain oversight. It does not create new regulatory authority or change approval standards; it makes existing processes more visible.
What the text implies
- Public disclosure of FDA-industry negotiation minutes may reveal the extent to which manufacturers influence regulatory timelines and safety standards, potentially triggering legislative or enforcement responses.
- Detailed processing metrics (approval rates by tier, average timelines) may expose FDA resource constraints or bottlenecks that have been obscured, creating pressure for budget increases or process reform.
- GAO supply-chain study may identify that current OTC monograph framework lacks real-time visibility into manufacturing disruptions, potentially leading to future legislation expanding FDA authority over OTC supply chains.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Ordinary citizens benefit from increased transparency into how the FDA approves OTC drugs and manages supply chains; public disclosure of negotiation minutes and processing timelines enables scrutiny of regulatory delays and industry influence. The GAO supply-chain study may identify gaps in FDA oversight that affect drug availability and affordability.
Named in the bill
FDA (Food and Drug Administration), GAO (Government Accountability Office), OTC monograph drug manufacturers, Contract manufacturing organizations, Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce
Where it stands
- Jul 29, 2025 — Introduced · Congress.gov: “Introduced in Senate”
- Jul 29, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
2 lobbying clients named this bill on 4 disclosure filings across 4 quarters, Sep 2025 to Sep 2026. Those filings disclosed $490,000 in lobbying spend. A filing names 5 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 36% of bills with at least one filing.
Tim Kaine, the sponsor, reported $132,858 in PAC receipts in the 2026 cycle.
- Haleon Us Holdings LLC — $430,000 on 2 filings
- Life360 — $60,000 on 2 filings
Lobbying Disclosure Act filings through Oct 21, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (5,079 characters) on Nov 7, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 17,910 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Sep 2025 to Sep 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Oct 21, 2026 · page rendered 2026-11-22.
“FDA must publish OTC drug approval timelines and negotiation records” QuorumCivic. https://share.quorumcivic.app/bill/119/s2513 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.